Company Regen BioPharma, Inc.

Equities

RGBP

US75886M3007

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Delayed OTC Markets Other stock markets 12:14:47 2024-04-24 pm EDT			5-day change	1st Jan Change
0.76 ^USD	+8.57%		+33.85%	-20.00%

Feb. 09	Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	CI
Jan. 19	Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients. tCellVax is a cell-based immunotherapy that stimulates the patientâs immune system through gene silencing of NR2F6.

Number of employees: 1

USD in Million	2022	Weight	2023	Weight	Delta
Regenerative Medical Applications 100.0 %	0	100.0 %	0	100.0 %	+0.44%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	0	100.0 %	+0.44%

Managers	Title	Age	Since
David Koos CEO	Chief Executive Officer	64	12-04-23

Members of the board	Title	Age	Since
David Koos CEO	Chief Executive Officer	64	12-04-23

	Vote	Quantity	Free-Float	Total Float
Stock A	0	29,338	0	99.99 %
Stock B	0	34	0
Stock C	1	3,750,565	3,750,061 ( 99.99 %)
Stock D	0	409,551	0

Name	Equities	%	Valuation
David Koos 0.0134 %	504	0.0134 %	378 $
Thompson Investment Management, Inc. 0.000107 %	4	0.000107 %	3 $

Name	Equities	%	Valuation
David Koos 0.6680 %	334	0.6680 %	251 $

Name	Equities	%	Valuation
David Koos 0.0243 %	7,667	0.0243 %	5 750 $
Harry Lander 0.0212 %	6,667	0.0212 %	5 000 $
Todd Caven 0.0212 %	6,667	0.0212 %	5 000 $
Jean-Pierre Millon 0.0127 %	4,001	0.0127 %	3 001 $
Robert D. Hopkins 0.006352 %	2,001	0.006352 %	1 501 $
Roger Formisano 0.006352 %	2,001	0.006352 %	1 501 $

Name	Equities	%	Valuation
David Koos 100.00 %	15,007	100.00 %	11 255 $

Name	Equities	%	Valuation
David Koos 29.84 %	122,221	29.84 %	318 997 $
RGBP Holdings LLC 9.999 %	40,949	9.999 %	106 877 $

Regen Biopharma, Inc.

4700 Spring Street Suite 304

91942, La Mesa

+619 722 5505

http://www.regenbiopharmainc.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
REGEN BIOPHARMA, INC.	-20.00%	2.92M
VERTEX PHARMACEUTICALS INCORPORATED	-1.74%	105B
REGENERON PHARMACEUTICALS, INC.	+3.49%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.52%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.68%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.11%	14.09B
SAREPTA THERAPEUTICS, INC.	+24.44%	10.99B

Bio Therapeutic Drugs